News on Mendelian diseases, hereditary cancer, variant classification, cystic fibrosis testing and more.
The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.
The company will donate full laboratory set-ups to the effort and provide training and education to implement screening programs.
The Rostock, Germany-based company reported €12.1 million ($13.6 million) in revenues, missing the average analyst estimate of $14.7 million.
The test has been developed to run on Illumina's NextSeq 550Dx next-generation sequencing platform and will be prepared for commercial launch in Europe.
Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.
